TRAVERE THERAPEUTICS, INC.
Equity & Debt
| Fiscal Year | Long Term Debt | Share Holder Equity | Cash on Hand |
|---|---|---|---|
| FY2016 | — | $307.8M | $41.0M |
| FY2017 | — | $293.1M | $99.4M |
| FY2018 | — | $318.3M | $102.9M |
| FY2019 | — | $221.2M | $62.4M |
| FY2020 | — | $211.2M | $84.8M |
| FY2021 | — | $302.1M | $165.8M |
| FY2022 | — | $42.9M | $61.7M |
| FY2023 | — | $200.8M | $58.2M |
| FY2024 | — | $59.1M | $58.5M |
| FY2025 | — | $114.8M | $93.0M |